Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) traded down 0.5% during trading on Friday . The company traded as low as $34.82 and last traded at $37.30. 1,160,993 shares traded hands during mid-day trading, a decline of 65% from the average session volume of 3,336,246 shares. The stock had previously closed at $37.49.
Analysts Set New Price Targets
Several research analysts have weighed in on TEM shares. Wolfe Research assumed coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Guggenheim initiated coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Loop Capital lifted their target price on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Bank of America increased their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Finally, Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Tempus AI has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.
Get Our Latest Report on Tempus AI
Tempus AI Price Performance
Insider Transactions at Tempus AI
In related news, COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total transaction of $792,200.00. Following the sale, the chief operating officer now directly owns 982,442 shares of the company’s stock, valued at $38,914,527.62. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the transaction, the insider now owns 16,164,449 shares in the company, valued at $694,263,084.55. This represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 865,041 shares of company stock worth $35,917,673.
Hedge Funds Weigh In On Tempus AI
A number of hedge funds have recently made changes to their positions in the business. Silverleafe Capital Partners LLC acquired a new stake in shares of Tempus AI during the 4th quarter valued at about $533,000. Franklin Resources Inc. grew its stake in shares of Tempus AI by 1.0% in the 3rd quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock valued at $45,920,000 after purchasing an additional 8,387 shares during the period. Tidal Investments LLC acquired a new position in shares of Tempus AI in the 3rd quarter worth approximately $7,633,000. Teachers Retirement System of The State of Kentucky raised its holdings in shares of Tempus AI by 6.3% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 126,500 shares of the company’s stock worth $7,160,000 after buying an additional 7,500 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Tempus AI by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after buying an additional 539 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
- Five stocks we like better than Tempus AI
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What Is WallStreetBets and What Stocks Are They Targeting?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- What Investors Need to Know About Upcoming IPOs
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.